Jefferies downgraded Lava Therapeutics (LVTX) to Hold from Buy with a price target of $1.50, down from $3, after the company entered into an agreement to be acquired by XOMA Royalty (XOMA) for between $1.16 and $1.24 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LVTX: